These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 23657371)

  • 21. An audience with...Luca Santarelli. Interview by Alexandra Flemming.
    Santarelli L
    Nat Rev Drug Discov; 2013 Jan; 12(1):14-5. PubMed ID: 23274461
    [No Abstract]   [Full Text] [Related]  

  • 22. An introduction to adaptive designs and adaptation in CNS trials.
    Dragalin V
    Eur Neuropsychopharmacol; 2011 Feb; 21(2):153-8. PubMed ID: 20888739
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Getting more mileage out of a tankful of new molecular entities?
    Cavalla D
    Drug Discov Today; 2004 Apr; 9(7):304-5. PubMed ID: 15037227
    [No Abstract]   [Full Text] [Related]  

  • 24. Clinical research in China and India: a paradigm shift in drug development.
    Singh R
    Drug Discov Today; 2006 Aug; 11(15-16):675-6. PubMed ID: 16846793
    [No Abstract]   [Full Text] [Related]  

  • 25. Drug development for CNS disorders: strategies for balancing risk and reducing attrition.
    Pangalos MN; Schechter LE; Hurko O
    Nat Rev Drug Discov; 2007 Jul; 6(7):521-32. PubMed ID: 17599084
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drugmakers seek gold in doc IT. What Pfizer, Merck see as needed services, critics tie to drug marketing.
    Romano M
    Mod Healthc; 2001 Oct; 31(44):6-7, 14. PubMed ID: 11715738
    [No Abstract]   [Full Text] [Related]  

  • 27. Copycat consolidation.
    Wadman M
    Nature; 2007 Sep; 449(7161):393. PubMed ID: 17898741
    [No Abstract]   [Full Text] [Related]  

  • 28. What Have Proteomic Studies Taught Us About Novel Drug Targets in Autism?
    Guest PC; Martins-de-Souza D
    Adv Exp Med Biol; 2017; 974():49-67. PubMed ID: 28353224
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New 2017 Data and Statistics for Pharmaceutical Products.
    Lindsley CW
    ACS Chem Neurosci; 2018 Jul; 9(7):1518-1519. PubMed ID: 30016875
    [No Abstract]   [Full Text] [Related]  

  • 30. Predictions and Statistics for the Best-Selling Drugs Globally and in the United States in 2018 and a Look Forward to 2024 Projections.
    Lindsley CW
    ACS Chem Neurosci; 2019 Mar; 10(3):1115. PubMed ID: 30889957
    [No Abstract]   [Full Text] [Related]  

  • 31. Drug discovery in autism: the need for a developmental context.
    Willemsen-Swinkels SH; Buitelaar JK
    Drug Discov Today; 2004 Jun; 9(11):473. PubMed ID: 15149620
    [No Abstract]   [Full Text] [Related]  

  • 32. Oncology business development global summit.
    Bockman JM; Nalam S
    IDrugs; 2005 Jan; 8(1):37-40. PubMed ID: 15650940
    [No Abstract]   [Full Text] [Related]  

  • 33. CNS research in the pharmaceutical industry. A personal view of how innovation could be promoted by clinical pharmacology.
    Horowski R
    Eur J Clin Pharmacol; 1995; 47(5):467-8. PubMed ID: 7720772
    [No Abstract]   [Full Text] [Related]  

  • 34. Choosing drug of choice from restrictive formulary.
    Bender KJ
    J Clin Psychopharmacol; 1997 Jun; 17(3):145-8. PubMed ID: 9169956
    [No Abstract]   [Full Text] [Related]  

  • 35. Efficacy, safety and cost of new drugs acting on the central nervous system.
    Garattini S; Bertele' V
    Eur J Clin Pharmacol; 2003 May; 59(1):79-84. PubMed ID: 12743674
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Momentum is building.
    Lindsley CW
    ACS Chem Neurosci; 2015 Feb; 6(2):207. PubMed ID: 25689884
    [No Abstract]   [Full Text] [Related]  

  • 37. Cost-effectiveness of nanomedicine: the path to a future successful and dominant market?
    Bosetti R
    Nanomedicine (Lond); 2015 Jul; 10(12):1851-3. PubMed ID: 26139120
    [No Abstract]   [Full Text] [Related]  

  • 38. Biotech slumps in Q1.
    Lawrence S
    Nat Biotechnol; 2008 May; 26(5):486. PubMed ID: 18464769
    [No Abstract]   [Full Text] [Related]  

  • 39. The art of self-defence.
    Gewin V
    Nature; 2008 Mar; 452(7186):498-500. PubMed ID: 18444262
    [No Abstract]   [Full Text] [Related]  

  • 40. Higher-functioning pervasive developmental disorders: rates and patterns of psychotropic drug use.
    Martin A; Scahill L; Klin A; Volkmar FR
    J Am Acad Child Adolesc Psychiatry; 1999 Jul; 38(7):923-31. PubMed ID: 10405512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.